- Home
- MPT vs DNLI Comparison
MPT vs DNLI Comparison
Compare MPT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPT | DNLI |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | 121 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | MPT | DNLI |
|---|---|---|
| Price | $5.20 | $19.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $5.00 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 4.8M | 1.4M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.91 | $408.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.51 | $12.58 |
| 52 Week High | $6.47 | $23.77 |
Technical Indicators
Market Signals| Indicator | MPT | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 51.01 |
| Support Level | $4.86 | $18.42 |
| Resistance Level | $6.47 | $20.35 |
| Average True Range (ATR) | 0.17 | 0.98 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 65.84 | 66.42 |
Price Performance
Historical ComparisonAbout MPT Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.